Develops inhalation-based drug delivery systems to provide targeted therapies for lung and systemic diseases, addressing the lack of effective treatment options for serious conditions. By leveraging specialized formulations and delivery technologies, it improves patient access to essential medications and enhances therapeutic efficacy.
Funding
$11.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many lung and systemic diseases lack effective treatment options, and traditional drug delivery methods may not provide targeted therapy to the affected areas. This can result in limited efficacy and increased side effects for patients.
Solution
Transpire Bio develops inhalation-based drug delivery systems designed to provide targeted therapies for both lung and systemic diseases. By leveraging specialized formulations and advanced delivery technologies, the company aims to improve patient access to essential medications and enhance therapeutic efficacy. Their approach focuses on delivering drugs directly to the site of disease, potentially reducing systemic exposure and improving patient outcomes. The company is committed to building a world-leading inhalation medicines company with a global reach and a patient-centric focus.
Target Audience
The primary target audience includes patients suffering from lung and systemic diseases, as well as healthcare providers seeking more effective and targeted treatment options.
Features
- Inhalation therapies for lung diseases
- Inhalation therapies for systemic diseases
- Development of specialized formulations for targeted drug delivery
- Advanced delivery technologies for efficient drug dispersion